Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Name: Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
Published: 2022
License: Public Domain

Pfizer · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

breast-cancer effectiveness japan

breast cancer, retrospective, multicenter, observational, effectiveness, real-world progression free survival, palbociclib, endocrine therapy, japan, hormone receptor positive/ human epidermal growth factor negative (hr+/her2-), advanced breast cancer, first-line therapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Related documents